Cystic Fibrosis News

At three follow-up visits within 6 months, reports of neuropsychological side effects rose or stayed stable among patients with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor therapy, according to results published in CHEST.

The FDA has approved Alyftrek for patients aged 6 years and older with cystic fibrosis with certain mutations, according to a press release from Vertex Pharmaceuticals.

Among patients with advanced cystic fibrosis lung disease, two cardiopulmonary exercise testing outcomes could predict death/lung transplantation, according to results published in Annals of the American Thoracic Society.

Percent-predicted FEV1 and respiratory-related quality of life improved with 28-day triple therapy in individuals with the N1303K cystic fibrosis transmembrane conductance defect, according to data published in Lancet Respiratory Medicine.

Patients with COPD, asthma and cystic fibrosis may soon be able to monitor their diseases by using/breathing through a tool that connects to their smartphone, according to a University of Pittsburgh press release.

BOSTON — Hospitalization for a cardiac cause vs. a noncardiac cause in patients with cystic fibrosis yielded elevated in-hospital mortality, according to a presentation at the CHEST Annual Meeting.

BOSTON — Having vs. not having past cystic fibrosis transmembrane conductance regulator modulator exposure did not change positive outcomes seen with elexacaftor/tezacaftor/ivacaftor, according to data presented at the CHEST Annual Meeting.

Lumacaftor/ivacaftor showed improvements in several measures in children aged 2 to 5 years homozygous for F508del-CFTR over 96 weeks, according to results published in Annals of the American Thoracic Society.

Lung clearance index and MRI scores improved in kids aged 6 to 11 years with cystic fibrosis and at least one F508del allele receiving elexacaftor/tezacaftor/ivacaftor therapy, according to results published in European Respiratory Journal.